Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis

Drug Discovery Today

Volumn 6, Issue 9, 2001, Pages 478-482

  Foda, Hussein D ^a   Zucker, Stanley ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE; PROTEINASE;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CORRELATION FUNCTION; ENDOTHELIUM CELL; ENZYME RELEASE; HUMAN; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; STROMA CELL; TUMOR; TUMOR GROWTH;

EID: 0035337023     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01752-4     Document Type: Review

References (66)

1. Tadpole collagenase. Preparation and purification
2. Collagenolyticactivity in amphibian tissues: a tissue culture assay
3. Metalloproteinases and their inhibitors in matrix remodeling
4. Matrix metalloprotease: a review
5. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interaction with tissue inhibitors of metalloproteinases
6. Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts
7. Concanavalin A produces a matrix-degradative phenotype in human fibroblasts
8. A matrix metalloproteinase expressed on the surface of invasive tumour cells
9. Mechanism of cell surface activation of 72 kDa type IV collagenase
10. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinae 1 (MT1-MMP)
11. Intermolecular autolytic cleavage can contribute to the activation of proglatinase A by cell membranes
12. Membrane associated matrix metalloproteinases in metastasis
13. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic
14. Activity of type IV collagenases in benign and malignant breast disease
15. Protease inhibitors: role and potential therapeutic use in human cancer
16. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line
17. Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer
18. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1
19. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
20. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency
21. Changing views of the role of matrix metalloproteinases in metastasis
22. Matrix metalloproteinases: biologic activity and clinical implications
23. Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revertant cell lines: not an invariant correlation with metastasis
24. Matrix metalloproteinases in tissue repair
25. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5
26. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5
27. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release
28. Matrix metalloproteinases: multifunctional contributors to tumor progression
29. Emerging roles for proteinases in cancer
30. Cancer cell invasion and metastasis
31. Tumor and host molecules important in the organ preference of metastasis
32. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
33. High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV
34. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis
35. 3
36. Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization
37. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily
38. Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers
39. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface
40. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion
41. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles
42. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
43. The role of angiogenesis in tumor growth
44. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma
45. The regulation of blood vessel growth by vascular endothelial growth factor
46. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
47. Interstitial collagenase is required for angiogenesis in vitro
48. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis
49. Matrix metalloproteinases
50. Metalloproteases in remodeling of vascular extracellular matrix
51. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention
52. Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type matrix metalloproteinase
53. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis
54. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells
55. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
56. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing
57. A link between integrin and MMPs in angiogensis
58. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
59. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells
60. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells
61. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium
62. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β3
63. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma
64. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
65. Matrix metalloproteinases generate angiostatin: effects on neovascularization
66. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance